The recurrence of this TPM3-NTRK1 gene fusion as an oncogene in colon cancer has been more recently confirmed, along with evidence that it is associated with sensitivity to TrkA inhibition [44]. This evidence concerns the gene NTRK1 and colonic neoplasm.